Page 3 - Updated Analysis News Today

AbbVie to Showcase Breadth of Oncology Portfolio and Pipeline at the 2021 ASCO and EHA Annual Congresses ABBVie will present results from 43 abstracts across 12 types of cancer during the upcoming virtual American Society of Clinical Oncology Annual Meeting and the virtual European Hematology Association congress . “We are advancing discovery and innovation to improve on the standards of care for blood cancer treatment,” said Mohamed Zaki M.D., Ph.D., vice president and global head of onco...

Click here to subscribe to the Multiple Sclerosis News Today Newsletter! 5 (2) Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Treatment with Tysabri (natalizumab) can improve mental and social health in people with multiple sclerosis (MS), according to new data presented at the 2021 virtual American Academy of Neurology ...

(diroximel fumarate) reinforce the treatment’s positive gastrointestinal tolerability profile Biogen advances leading research to help inform future patient management including new information on the clinical profile of extended interval dosing with natalizumab CAMBRIDGE, Mass., April 16, 2021 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced new data from its industry-leading portfolio of multiple sclerosis (MS) therapies to be presented at the American Academy of Neurology...

Biogen Inc.: New Data at AAN 2021 from Across Biogens MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis (natalizumab) can lead to meaningful improvements in mental and social health compared to Ocrevus (ocrelizumab) (diroximel fumarate) reinforce the treatments positive gastrointestinal tolerability profile Biogen advances leading research to help inform future patient management including new information on the clinical profile of exte...

Press release content from Business Wire. The AP news staff was not involved in its creation. New Genentech Data at 2021 AAN Highlight Impact and Breadth of Expanding Neuroscience Portfolio April 8, 2021 GMT SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr 8, 2021-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Ac...

(0) EVRYSDI 2-year FIREFISH Part 2 data show improvement in motor function in infants with Type 1 spinal muscular atrophy (SMA) OCREVUS data show its consistent benefit on slowing disease progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS) Data for ENSPRYNG in neuromyelitis optica spectrum disorder (NMOSD) reinforce safety and efficacy, including in patients with concomitant autoimmune diseases (CAIDs) Data for investigational MS medicine fenebrutinib support it...

Global IoT in Aviation Market 2020 Updated Analysis: Industry Insights and Forecast to 2030